Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment
June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] READ MORE
Jane Salmon, MD – Determined to Help Pregnant Women Triumph Over Lupus
March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize in lupus research because it was there that she felt she could be of greatest value. “There were so many unknowns in lupus with all its complexity. Here was a disease primarily affecting young women […] READ MORE
Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] READ MORE
Catch Up on LRA News with Lupus Research Update Vol. 1, 2022
February 17, 2022 It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year in our first Lupus Research Update of 2022. The Lupus Research Alliance (LRA) made important gains on many fronts—thanks to tremendous friends like you. I hope you share my pride because your support continues to be the catalyst behind every LRA accomplishment. […] READ MORE
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY. A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] READ MORE
LRA-Funded Research Aims at Preventing Heart Disease in Kids With Lupus
February 14, 2022 Being a kid isn’t always easy, but growing up with lupus makes it a much harder challenge. That’s why Harvard University’s Associate Professor Dr. Joyce Chang has a special place in her heart for these kids and chose to focus her career on their care. In honor of American Heart Month, we […] READ MORE
LRA-Funded Research Found a Connection Between the Epstein-Barr Virus Infection and MS as an Autoimmune Disease
February 4, 2022 A potential new cause of the autoimmune disease multiple sclerosis (MS) was discovered by researchers partly funded by the Lupus Research Alliance. Published in the prestigious journal Nature, the study results provide strong evidence that a virus can trigger the development of MS. The LRA invested in this work to help understand […] READ MORE
Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research
January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE
Pivotal LRA-Funded Research Shared at Annual Rheumatology Meeting
November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […] READ MORE
Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting
November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] READ MORE
A “Call to Arms” for the Lupus Community
August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […] READ MORE
Positive Research Results on Potential Lupus Treatments Shared at Major Medical Meeting
June 8, 2021 The annual European Congress of Rheumatology (EULAR 2021) brought much good news of potential new treatments for systemic lupus erythematosus (SLE). Following are highlights: Rituximab Plus Belimumab Taking belimumab after rituximab may help lupus according to data from the BEAT-LUPUS trial presented at the 2021 EULAR Virtual Congress by the trial lead investigator […] READ MORE
